Cover ImageSALE
市場調查報告書

美國的固態腫瘤檢驗市場:2018年∼2022年

Solid Tumor Testing Market in the US 2018-2022

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 353218
出版日期 內容資訊 英文 109 Pages
訂單完成後即時交付
價格
Back to Top
美國的固態腫瘤檢驗市場:2018年∼2022年 Solid Tumor Testing Market in the US 2018-2022
出版日期: 2018年05月03日 內容資訊: 英文 109 Pages
簡介

關於固態腫瘤檢驗

固態腫瘤檢驗,是有助於癌症的早期發現的醫療治療。為了不讓癌症細胞擴散,實現有效的治療而進行。

Technavio的分析師預測著,美國的固態腫瘤檢驗市場從2018年到2022年之間將以10.72%的年複合成長率成長。

本報告提供美國的固態腫瘤檢驗市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 市場情形

  • 市場生態系統
  • 市場特性
  • 市場區隔分析

第5章 市場規模

  • 市場定義
  • 市場規模(2017年)
  • 市場規模及預測(2017-2022年)

第6章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情形

第7章 市場區隔:各技術

  • 市場區隔:各技術(2017-2022年)
  • 比較:各技術
  • 傳統的檢驗 - 市場規模與預測
  • 非傳統的檢驗 - 市場規模與預測
  • 市場機會:各技術

第8章 客戶形勢

第9章 分割:各終端用戶

  • 市場區隔:各終端用戶(2017-2022年)
  • 比較:各終端用戶
  • 醫院 - 市場規模與預測
  • 診斷研究所 - 市場規模與預測
  • 學術機構及研究機關 - 市場規模與預測
  • 市場機會:各終端用戶

第10章 決策架構

第11章 成長要素與課題

  • 市場成長要素
  • 市場課題

第12章 市場趨勢

  • 癌症診斷的NGS的採用
  • 對傳統的切片檢查的液態生物檢體的優先
  • 癌症研究的投資的增加

第13章 業者情勢

  • 概要
  • 創造性破壞狀況

第14章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Agilent Technologies
  • Becton, Dickinson and Company
  • Danaher
  • F. Hoffmann-La Roche
  • Illumina
  • Thermo Fisher Scientific

第15章 附錄

  • 簡稱的清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR21773

About Solid Tumor Testing

Solid tumor testing is a medical procedure that helps in the early detection of cancer. It is done to avoid the spread of cancerous cells throughout the body and allow for effective treatment.

Technavio's analysts forecast the solid tumor testing market in the US to grow at a CAGR of 10.72% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the solid tumor testing market in the US for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

Technavio's report, Solid Tumor Testing Market in the US 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Agilent Technologies
  • Becton, Dickinson and Company
  • Danaher
  • F. Hoffmann-La Roche
  • Illumina
  • Thermo Fisher Scientific

Market driver

  • Growing prevalence of cancer
  • For a full, detailed list, view our report

Market challenge

  • High cost of sequencing
  • For a full, detailed list, view our report

Market trend

  • Adoption of NGS in cancer diagnostics
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY TECHNOLOGY

  • Segmentation by technology
  • Comparison by technology
  • Conventional testing - Market size and forecast 2017-2022
  • Non-conventional testing - Market size and forecast 2017-2022
  • Market opportunity by technology

PART 08: CUSTOMER LANDSCAPE

PART 09: SEGMENTATION BY END-USER

  • Segmentation by end-user
  • Comparison by end-user
  • Hospitals - Market size and forecast 2017-2022
  • Diagnostic laboratories - Market size and forecast 2017-2022
  • Academic and research institutes - Market size and forecast 2017-2022
  • Market opportunity by end-user

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Adoption of NGS in cancer diagnostics
  • Preference for liquid biopsy over traditional biopsy
  • Increase in investment in cancer research

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Agilent Technologies
  • Becton, Dickinson and Company
  • Danaher
  • F. Hoffmann-La Roche
  • Illumina
  • Thermo Fisher Scientific

PART 15: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Related market
  • Exhibit 02: Market characteristics
  • Exhibit 03: Market segments
  • Exhibit 04: Market definition - Inclusions and exclusions checklist
  • Exhibit 05: Market size 2017
  • Exhibit 06: Validation techniques employed for market sizing 2017
  • Exhibit 07: Solid tumor testing market in the US- Market size and forecast 2017-2022 ($ bn)
  • Exhibit 08: Solid tumor testing market in the US - Year-over-year growth 2018-2022 (%)
  • Exhibit 09: Five forces analysis 2017
  • Exhibit 10: Five forces analysis 2022
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2017 and 2022
  • Exhibit 17: Solid tumor testing market in the US by technology - Market share 2017-2022 (%)
  • Exhibit 18: Comparison by technology
  • Exhibit 19: Conventional tests for solid tumors associated with various types of cancer
  • Exhibit 20: Conventional testing - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 21: Conventional testing - Year over year growth 2018-2022 (%)
  • Exhibit 22: Non-conventional testing - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 23: Non-conventional testing - Year over year growth 2018-2022 (%)
  • Exhibit 24: Market opportunity by technology
  • Exhibit 25: Customer landscape
  • Exhibit 26: Solid tumor testing market in the US by end-user - Market share 2017-2022 (%)
  • Exhibit 27: Comparison by end-user
  • Exhibit 28: Hospitals - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 29: Hospitals - Year over year growth 2018-2022 (%)
  • Exhibit 30: Diagnostic laboratories - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 31: Diagnostic laboratories - Year over year growth 2018-2022 (%)
  • Exhibit 32: R&D funding for cancer 2013-2016 ($ millions)
  • Exhibit 33: Academic and research institutes- Market size and forecast 2017-2022 ($ bn)
  • Exhibit 34: Academic and research institutes - Year over year growth 2018-2022 (%)
  • Exhibit 35: Market opportunity by end-user
  • Exhibit 36: Cost of sequencing per genome 2001-2015 ($)
  • Exhibit 37: Vendor landscape
  • Exhibit 38: Landscape disruption
  • Exhibit 39: Vendors covered
  • Exhibit 40: Vendor classification
  • Exhibit 41: Market positioning of vendors
  • Exhibit 42: Agilent Technologies overview
  • Exhibit 43: Agilent Technologies- Business segments
  • Exhibit 44: Agilent Technologies - Organizational developments
  • Exhibit 45: Agilent Technologies - Geographic focus
  • Exhibit 46: Agilent Technologies - Segment focus
  • Exhibit 47: Agilent Technologies - Key offerings
  • Exhibit 48: Becton, Dickinson and Company overview
  • Exhibit 49: Becton, Dickinson and Company - Business segments
  • Exhibit 50: Becton, Dickinson and Company - Organizational developments
  • Exhibit 51: Becton, Dickinson and Company - Geographic focus
  • Exhibit 52: Becton, Dickinson and Company - Segment focus
  • Exhibit 53: Becton, Dickinson and Company - Key offerings
  • Exhibit 54: Danaher overview
  • Exhibit 55: Danaher - Business segments
  • Exhibit 56: Danaher - Organizational developments
  • Exhibit 57: Danaher- Geographic focus
  • Exhibit 58: Danaher- Segment focus
  • Exhibit 59: Danaher - Key offerings
  • Exhibit 60: F. Hoffmann-La Roche overview
  • Exhibit 61: F. Hoffmann-La Roche- Business segments
  • Exhibit 62: F. Hoffmann-La Roche - Organizational developments
  • Exhibit 63: F. Hoffmann-La Roche- Geographic focus
  • Exhibit 64: F. Hoffmann-La Roche- Segment focus
  • Exhibit 65: F. Hoffmann-La Roche - Key offerings
  • Exhibit 66: Illumina overview
  • Exhibit 67: Illumina - Business segments
  • Exhibit 68: Illumina - Organizational developments
  • Exhibit 69: Illumina - Geographic focus
  • Exhibit 70: Illumina - Segment focus
  • Exhibit 71: Illumina - Key offerings
  • Exhibit 72: Thermo Fisher Scientific overview
  • Exhibit 73: Thermo Fisher Scientific- Business segments
  • Exhibit 74: Thermo Fisher Scientific- Organizational developments
  • Exhibit 75: Thermo Fisher Scientific- Geographic focus
  • Exhibit 76: Thermo Fisher Scientific- Segment focus
  • Exhibit 77: Thermo Fisher Scientific- Key offerings
Back to Top